IMR Stock Overview
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
AC Immune SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.76 |
52 Week High | US$4.65 |
52 Week Low | US$1.60 |
Beta | 1.02 |
1 Month Change | -15.34% |
3 Month Change | -37.20% |
1 Year Change | 31.81% |
3 Year Change | -56.84% |
5 Year Change | -35.81% |
Change since IPO | -80.29% |
Recent News & Updates
Recent updates
Shareholder Returns
IMR | DE Biotechs | DE Market | |
---|---|---|---|
7D | -7.7% | 2.1% | 1.9% |
1Y | 31.8% | 37.0% | 7.3% |
Return vs Industry: IMR underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: IMR exceeded the German Market which returned 7.3% over the past year.
Price Volatility
IMR volatility | |
---|---|
IMR Average Weekly Movement | 11.7% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IMR's share price has been volatile over the past 3 months.
Volatility Over Time: IMR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 147 | Andrea Pfeifer | https://www.acimmune.com |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer’s disease (AD).
AC Immune SA Fundamentals Summary
IMR fundamental statistics | |
---|---|
Market cap | €246.47m |
Earnings (TTM) | -€55.37m |
Revenue (TTM) | €15.11m |
16.3x
P/S Ratio-4.5x
P/E RatioIs IMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMR income statement (TTM) | |
---|---|
Revenue | CHF14.80m |
Cost of Revenue | CHF54.61m |
Gross Profit | -CHF39.80m |
Other Expenses | CHF14.43m |
Earnings | -CHF54.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.58 |
Gross Margin | -268.93% |
Net Profit Margin | -366.41% |
Debt/Equity Ratio | 0% |
How did IMR perform over the long term?
See historical performance and comparison